collegiumpharma.com - COLL Enterprise Value-to-Revenue Multiple

Collegium Pharmaceutical operates amid intense competition and pressure from generics. Strict DEA oversight and government price controls create significant barriers to entry. However, the company maintains its position through the abuse-deterrent properties of Belbuca. The EV/Revenue multiple reflects the valuation trend, with the metric holding around 2240.45, as clearly illustrated in the chart below.
COLL (Collegium Corp): analytical breakdowns and indicator data

Collegium Pharmaceutical maintains its leadership in pain therapy through unique abuse-deterrent drug technologies. The EV/Sales multiple quantifies the market value of these innovations by comparing the total cost of acquiring the business with the volume of generated revenue. This indicator eliminates the impact of debt load, revealing the gap between the share price and real assets. Exceeding average values signals an overpayment. By analyzing the EV/Sales multiple, an investor determines the fair price per unit of sales.